FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Disclosed is a neutralizing monoclonal antibody or antigen-binding fragment thereof, selectively binding a rabies virus glycoprotein comprising variable regions of heavy (VH) and light (VL) chains. Variable immunoglobulin heavy chain (VH) domain includes a sequence of hypervariable regions CDRH1 with SEQ ID NO: 1, CDRH2 with SEQ ID NO: 2 and CDRH3 with SEQ ID NO: 3, and the variable immunoglobulin light chain (VL) domain comprises a sequence of hypervariable regions CDRL1 with SEQ ID NO: 4, CDRL2 with SEQ ID NO: 5 and CDRL3 with SEQ ID NO: 6. Also disclosed is a neutralizing monoclonal antibody or antigen-binding fragment thereof, selectively binding a rabies virus glycoprotein comprising a heavy chain variable region (VH) comprising an amino acid sequence not less than 90 % homologous with SEQ ID NO: 7, and a light chain variable region (VL) comprising an amino acid sequence not less than 90 % homologous to SEQ ID NO: 8.
EFFECT: invention enables to obtain an antibody with high affinity.
4 cl, 2 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION BASED ON NEUTRALIZING MONOCLONAL ANTIBODIES BINDING WITH GLYCOPROTEIN OF RABIES VIRUS | 2018 |
|
RU2711553C1 |
| HUMANISED 5D3HU ANTIBODY BINDING TO THE PRAME TUMOUR ANTIGEN, DNA FRAGMENTS ENCODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY | 2020 |
|
RU2761876C1 |
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2639533C2 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2630304C2 |
| MONOCLONAL ANTIBODY, LINKING WITH E-BIR VIRUS GLOBE-PROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2016 |
|
RU2644334C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
